Luminex Corp. (LMNX)

21.31
NASDAQ : Health Technology
Prev Close 21.73
Day Low/High 21.30 / 21.81
52 Wk Low/High 20.24 / 35.37
Avg Volume 288.00K
Exchange NASDAQ
Shares Outstanding 44.98M
Market Cap 977.35M
EPS 0.40
P/E Ratio 155.21
Div & Yield 0.24 (1.11%)

Ratings Changes To Be Publicly Issued on 8/1/13

Upgrades: ARE, BBOX, BFS, CAFI, ELGX, HT, LBY, LMNX, MAS, SEM, TFSL, UMH, VSB Downgrades: ADVS, RDY, UDR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

LMNX: Insiders Vs. Shorts

LMNX: Insiders Vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 05/31/2013 settlement date, and Luminex Corp is one of the most shorted stocks of the Russell 3000, based on 9.62 "days to cover" versus the median component at 4.86. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Top Insider Trades: TSLA, MOSY, WWWW, LMNX

Top Insider Trades: TSLA, MOSY, WWWW, LMNX

The top 10 open-market insider purchases and sales filed at the SEC Monday.

Bullish Two Hundred Day Moving Average Cross - LMNX

Bullish Two Hundred Day Moving Average Cross - LMNX

In trading on Tuesday, shares of Luminex Corp crossed above their 200 day moving average of $17.70, changing hands as high as $18.06 per share. Luminex Corp shares are currently trading up about 2.9% on the day.

Merck And Luminex Corporation Enter Agreement To Develop Companion Diagnostic To Support Investigational BACE Inhibitor Clinical Development Program For Alzheimer’s Disease

Merck And Luminex Corporation Enter Agreement To Develop Companion Diagnostic To Support Investigational BACE Inhibitor Clinical Development Program For Alzheimer’s Disease

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be ...

Luminex Corporation Stock Downgraded (LMNX)

Luminex Corporation Stock Downgraded (LMNX)

Luminex Corporation (Nasdaq:LMNX) has been downgraded by TheStreet Ratings from from a buy to hold.

Luminex Stock Hits New 52-Week High (LMNX)

Luminex Stock Hits New 52-Week High (LMNX)

Luminex Corporation (Nasdaq:LMNX) hit a new 52-week high Monday as it is currently trading at $25.22, above its previous 52-week high of $25.16 with 224,713 shares traded as of 2:05 p.m. ET. Average volume has been 318,600 shares over the past 30 days.

Luminex Rises On Unusually High Volume (LMNX)

Luminex Rises On Unusually High Volume (LMNX)

Luminex Corporation (Nasdaq:LMNX) is trading at unusually high volume Tuesday with one million shares changing hands. It is currently at 4.4 times its average daily volume and trading up 72 cents (+3.2%).

Time to Dive Into Luminex, Pool Corp.

Time to Dive Into Luminex, Pool Corp.

In this episode of Buy This, Sell That!, George Young, portfolio manager for the Villere Balanced Fund, names his favorite stocks including Pool Corp. and Luminex.

7 Stocks Soaring on Unusual Volume

7 Stocks Soaring on Unusual Volume

Onyx and Monolithic Power are among the stocks gaining with high volume. A large spike in volatility could be next.

Luminex Reaches New 52-Week High (LMNX)

Luminex Reaches New 52-Week High (LMNX)

Luminex Corporation (Nasdaq:LMNX) hit a new 52-week high Friday as it is currently trading at $24.75, above its previous 52-week high of $24.70 with 134,613 shares traded as of 1:49 p.m. ET. Average volume has been 248,600 shares over the past 30 days.

Luminex Corporation Stock Upgraded (LMNX)

Luminex Corporation Stock Upgraded (LMNX)

Luminex Corporation (Nasdaq:LMNX) has been upgraded by TheStreet Ratings from a hold to buy.

Luminex Corporation Stock Downgraded (LMNX)

Luminex Corporation Stock Downgraded (LMNX)

Luminex Corporation (Nasdaq:LMNX) has been downgraded by TheStreet Ratings from from a buy to hold.

Luminex Reaches New 52-Week High (LMNX)

Luminex Reaches New 52-Week High (LMNX)

Luminex Corporation (Nasdaq:LMNX) hit a new 52-week high Tuesday as it is currently trading at $22.51, above its previous 52-week high of $21.89 with 284,119 shares traded as of 10:06 a.m. ET. Average volume has been 174,400 shares over the past 30 days.

Luminex Corporation Stock Upgraded (LMNX)

Luminex Corporation Stock Upgraded (LMNX)

Luminex Corporation (Nasdaq:LMNX) has been upgraded by TheStreet Ratings from a hold to buy.

Two Insiders Buy $2.6M Worth of CNA Financial

Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.

Luminex Gets Approval For Screening Test

FDA grants approval for Luminex cystic fibrosis test

Earnings Roundup: Luminex, Arena Resources

Earnings Roundup: Luminex, Arena Resources

Earnings roundup: Luminex 1st-qtr results fall short, Arena Resources profit slides with oil

Luminex Reports 1Q Loss On Settlement Charge

Luminex Reports 1Q Loss On Settlement Charge

Luminex reports 1st-quarter loss on settlement charge, lowers revenue outlook

Luminex's Earnings Take a Deep Dive

Company is hurt by no gain on a settlement and prior-year liability.

This Week's 'Barron's' Roundup

This Week's 'Barron's' Roundup

Longtime bear Barry Ritholtz gets bullish, while Westwood's Nick Galluccio offers up small-cap picks.

Health Winners & Losers: Luminex

Health Winners & Losers: Luminex

Accuray falls 16%.

Analysts' Upgrades, Downgrades: Hershey

See who made what calls.

Signs Pointing to a Deep Recessionary Period

But thanks to the decent earnings reports this week, the hopeful side of the equation currently has the upper hand.

Friday's Winners & Losers: TerreStar

Shares shoot up 24% after the company announces it has secured a $200 million investment from EchoStar.

Friday's Health Winners & Losers

Labopharm climbs on drug study results.

Thursday's Healthcare Winners & Losers

Sciele jumps on FDA approval.

Thursday's Health Winners & Losers

Luminex is higher.

Thursday's Small-Cap Winners & Losers

Aetrium dives more than 30%.

Microsoft's Not Done Yet

The software giant has started moving up again. Plus the Dow, Conexant and more.

TheStreet Quant Rating: C (Hold)